Joint mobility

"Joint mobility" is not a molecule, receptor, or canonical therapeutic target. Instead, it refers to the capacity of a joint to move through its full range of motion, which is determined by the anatomical structure and health of the joint as well as surrounding tissues such as ligaments, cartilage, synovial fluid, and muscles. Joints must balance mobility with stability; too much stability limits movement while excessive mobility can lead to dislocation or injury[2][4]. Synovial joints are primarily responsible for large ranges of movement in vertebrates due to their unique structure—featuring a synovial cavity filled with lubricating fluid and articular cartilage covering bone ends—which allows for gliding, angular, rotational, and special movements (e.g., flexion/extension)[4]. Joint mobility is affected by factors such as age, disease (notably osteoarthritis or rheumatoid arthritis), trauma/injury to connective tissues or cartilage degradation[1][3]. It is an important clinical measure but does not represent a discrete molecular entity that can be directly targeted by drugs. Rather than being a single targetable molecule or receptor involved in signal transduction or cellular processes like enzymes or ion channels are, "joint mobility" describes an emergent property resulting from the integrated function of multiple tissue types within the joint organ system. Because "joint mobility" does not correspond to any specific protein/gene/receptor/enzyme/transporter/etc., it should not be considered a valid entry for structured drug-target databases.

Other names

Joint flexibilityRange of motion (ROM)Articular mobility